PNPLA3 is associated with an increased risk for NAFLD across the full spectrum of the disease including age of diagnosis, steatosis, fibrosis, and hepatocellular carcinoma (HCC) (7, 8). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.